Modality
Peptide
MOA
SGLT2i
Target
BCMA
Pathway
Hedgehog
Gastric CaCKD
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
~Nov 2021
→ ~Feb 2023
Phase 2
May 2023
→ Nov 2025
Phase 2Current
NCT08717468
999 pts·CKD
2024-06→2025-11·Active
NCT03901262
760 pts·CKD
2023-05→TBD·Not yet recruiting
1,759 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-135mo agoPh3 Readout· CKD
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q4
P2/3
Not yet…
P2/3
Active
Catalysts
Ph3 Readout
2025-11-13 · 5mo ago
CKD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08717468 | Phase 2/3 | CKD | Active | 999 | Mayo |
| NCT03901262 | Phase 2/3 | CKD | Not yet recr... | 760 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 |